Vaxcyte Inc. (PCVX)
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 66.60 -0.54%
PCVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.96B
- EPS (TTM)
- -$7.62
- Dividend yield
- None
- 52-week range
- 39.87 – 90.75
- Day range
- 64.27 – 67.15
- Volume / Avg
- 11.56M / 1.50M
- Beta
- —
- Shares outstanding
- 148.81M
- Next earnings
- Nov 3, 2026
52-week range
PCVX stock today
Shares of Vaxcyte (PCVX) finished higher on Oct 7 at $66.96, a gain of 0.39% or $0.26 per share, versus the S&P 500's 0.22% decline. Volume was 7.7x the average at 11.56M shares, a sign of unusually heavy trading. Shares are 26.2% below their 52-week high of $90.75, set on Oct 5, 2026 and 67.9% above the 52-week low of $39.87, in the middle of the past year's range.
PCVX is up 45.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 59.9%. Vaxcyte has posted a net loss over the last twelve months (EPS of -$7.62), so its P/E ratio is not meaningful. Vaxcyte's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Vaxcyte
Company profileVaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Grant E. Pickering M.B.A.
- Headquarters
- San Carlos, CA
- Employees
- 507
- IPO year
- 2020
- Website
- vaxcyte.com
Financial highlights
Full financialsVaxcyte reported a net loss of $766.6 million, compared with a loss of $463.9 million a year earlier. Diluted earnings per share came in at -$5.63.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-766.63M | $-463.93M | $-402.27M | $-223.49M | $-100.08M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$110.88+65.59%
- Strong buy 1
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $2.00
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-1.97 vs —
PCVX news
All PCVX news- Stocks Finish Higher on Lower Bond Yields and Earnings OptimismNasdaqALK, GOOGL, UAL, AMAT
- S&P 500 and Nasdaq 100 Post Record Highs as Crude Prices and Bond Yields FallNasdaqALK, UAL, SLB, GNTX
- Stocks Climb as Inflation Risks Ease and Bond Yields DeclineNasdaqALK, GOOGL, UAL, AAPL
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersInvestor's Business DailyPCVX, MRNA
- Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5%NasdaqCRL, HTFL, ILMN, INFU
- Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine StudyInvestor's Business DailyPCVX, PFE
Vaxcyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs PCVX |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs PCVX |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs PCVX |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs PCVX |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs PCVX |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs PCVX |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs PCVX |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs PCVX |
Indexes, lists and sector
Vaxcyte stock FAQ
What is Vaxcyte's stock price today?
PCVX last traded at $66.96 as of Oct 7, 4:00 PM EDT, up 0.39% on the day. Prices are delayed at least 15 minutes.
When is Vaxcyte's next earnings date?
Vaxcyte is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $2.00.
Who is Vaxcyte's CEO?
Mr. Grant E. Pickering M.B.A. is the chief executive officer of Vaxcyte Inc., which has about 507 employees.
What is the PCVX 52-week high?
The 52-week high for PCVX is $90.75 and the 52-week low is $39.87. The stock is currently 26.2% below its high.